SKUP³ trial: comment

The paper on uvulopalatopharyngoplasty (the SKUP³ trial, September 2013 issue of Thorax) is a significant contribution to the literature on the surgical management of obstructive sleep apnea (OSA). The authors are to be congratulated on pushing through such a difficult trial with good control subjects. However, there is one concern that we have, which may alter the clinical conclusions that should be drawn. Patients for this trial were highly selected. In particular, none had had a previous tonsillectomy, and Friedman stage III (ie, only small tonsils) were specifically excluded. The Friedman stage I and II patients entered into this study had large tonsils by definition or, when there were only small tonsils, the tongue was low (suggesting they might still be important). Thus this study was very much one of tonsil resection with an added, and limited, palatal resection. Therefore we do not know which bit of the operation contributed most to the fall in apnea-hypopnea index (AHI). The authors imply from their study and from previous data that, because tonsil size did not predict degree of surgical benefit, the tonsil resection contribution to outcome was likely to be limited. However, this argument is possibly flawed. Tonsillar enlargement is known to be important, and patients with OSA will present with symptoms when the tonsils reach whatever is the critical size in that patient to cause obstruction, and this size is likely to depend on underlying pharyngeal dimensions (as it does in children). Thus their removal, whatever the critical size reached, will help relieve OSA. We would be reluctant, based on this study, to ascribe surgical success to the palatal resection component (perhaps implied by the article’s title) and wonder if the success results more from the tonsillectomy, as is the case in children. This trial should not be used as evidence to support palatal resection in OSA, especially given that this operation adversely influences the future use of continuous positive airway pressure (CPAP), should this be required.

John Stradling, Malcolm Kohler

1Oxford Centre for Respiratory Medicine, Oxford University, Churchill Hospital Campus, Oxford, UK
2Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland

Correspondence to Professor J Stradling, Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford OX3 7LJ, UK; john.stradling@orh.nhs.uk

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.


Received 4 September 2013
Accepted 3 October 2013
Published Online First 22 October 2013

http://dx.doi.org/10.1136/thoraxjnl-2013-204622

Thorax 2014;69:386.
doi:10.1136/thoraxjnl-2013-204476

REFERENCES

SKUP³ trial: comment

John Stradling and Malcolm Kohler

Thorax 2014 69: 386 originally published online October 21, 2013
doi: 10.1136/thoraxjnl-2013-204476

Updated information and services can be found at:
http://thorax.bmj.com/content/69/4/386.1

These include:

References
This article cites 5 articles, 1 of which you can access for free at:
http://thorax.bmj.com/content/69/4/386.1#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/